| Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ... MedRxiv, 2020.06. 22.20137273, 2020 | 12548* | 2020 |
| The global burden of cancer 2013 C Fitzmaurice, D Dicker, A Pain, H Hamavid, M Moradi-Lakeh, ... JAMA oncology 1 (4), 505-527, 2015 | 2915 | 2015 |
| Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying … CJL Murray, RM Barber, KJ Foreman, AA Ozgoren, F Abd-Allah, SF Abera, ... The Lancet 386 (10009), 2145-2191, 2015 | 2542* | 2015 |
| Global distribution and prevalence of hepatitis C virus genotypes JP Messina, I Humphreys, A Flaxman, A Brown, GS Cooke, OG Pybus, ... Hepatology 61 (1), 77-87, 2015 | 2238 | 2015 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2234* | 2021 |
| Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing TM Rawson, LSP Moore, N Zhu, N Ranganathan, K Skolimowska, ... Clinical infectious diseases 71 (9), 2459-2468, 2020 | 2010 | 2020 |
| The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 JD Stanaway, AD Flaxman, M Naghavi, C Fitzmaurice, T Vos, I Abubakar, ... The Lancet 388 (10049), 1081-1088, 2016 | 1625 | 2016 |
| A living WHO guideline on drugs for covid-19 A Agarwal, BJ Hunt, M Stegemann, B Rochwerg, F Lamontagne, ... bmj 370, 2020 | 1084* | 2020 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 1007 | 2022 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 843 | 2021 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 839 | 2020 |
| Oral versus intravenous antibiotics for bone and joint infection HK Li, I Rombach, R Zambellas, AS Walker, MA McNally, BL Atkins, ... New England Journal of Medicine 380 (5), 425-436, 2019 | 805 | 2019 |
| Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015 SS Lim, K Allen, ZA Bhutta, L Dandona, MH Forouzanfar, N Fullman, ... The Lancet 388 (10053), 1813-1850, 2016 | 696 | 2016 |
| Genetics of susceptibitlity to human infectious disease GS Cooke, AVS Hill Nature Reviews Genetics 2 (12), 967-977, 2001 | 614 | 2001 |
| Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study B Hanley, KN Naresh, C Roufosse, AG Nicholson, J Weir, GS Cooke, ... The Lancet Microbe 1 (6), e245-e253, 2020 | 602 | 2020 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 576* | 2019 |
| Technologies for global health P Howitt, A Darzi, GZ Yang, H Ashrafian, R Atun, J Barlow, A Blakemore, ... The Lancet 380 (9840), 507-535, 2012 | 524 | 2012 |
| MAIT cells are activated during human viral infections B Van Wilgenburg, I Scherwitzl, EC Hutchinson, T Leng, A Kurioka, ... Nature communications 7 (1), 11653, 2016 | 517 | 2016 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 476* | 2021 |
| The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa M Lemoine, Y Shimakawa, S Nayagam, M Khalil, P Suso, J Lloyd, ... Gut 65 (8), 1369-1376, 2016 | 430 | 2016 |
Helen WardProfessor of Public Health, Imperial CollegeVerified email at imperial.ac.uk
